Vaxzevria (COVID-19 vaccine)

URI: https://gptkb.org/entity/Vaxzevria_(COVID-19_vaccine)
GPTKB entity
Statements (33)
Predicate Object
gptkbp:instanceOf vaccine
gptkbp:age adults 18 years and older
gptkbp:alsoKnownAs gptkb:AZD1222
gptkb:Covishield
gptkbp:approvedBy gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
December 2020
gptkbp:category gptkb:COVID-19_vaccines
AstraZeneca products
gptkbp:contains replication-deficient chimpanzee adenovirus vector
SARS-CoV-2 spike protein genetic material
gptkbp:developedBy gptkb:University_of_Oxford
gptkb:AstraZeneca
gptkbp:dosingSchedule two doses
gptkbp:emergencyServices gptkb:European_Union
gptkb:India
gptkb:United_Kingdom
https://www.w3.org/2000/01/rdf-schema#label Vaxzevria (COVID-19 vaccine)
gptkbp:intervalBetweenDoses 4–12 weeks
gptkbp:manufacturer gptkb:India
gptkb:United_Kingdom
gptkb:Serum_Institute_of_India
gptkbp:routeOfAdministration intramuscular injection
gptkbp:sideEffect fever
fatigue
headache
rare blood clotting events
gptkbp:storage 2–8°C
gptkbp:target gptkb:COVID-19
gptkbp:technology viral vector vaccine
gptkbp:WHOEmergencyUseListing February 2021
gptkbp:bfsParent gptkb:AstraZeneca_plc
gptkbp:bfsLayer 7